Emma Titmuss

Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial.

Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial.

Journal: Journal for immunotherapy of cancer

Published: November 11, 2024

Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors.

Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors.

Journal: Cancer research communications

Published: October 31, 2024

Correction: Titmuss et al. Immune Activation Following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study. Int. J. Mol. Sci. 2023, 24, 5869.

Correction: Titmuss et al. Immune Activation Following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study. Int. J. Mol. Sci. 2023, 24, 5869.

Journal: International journal of molecular sciences

Published: October 12, 2024

Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma.

Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma.

Journal: iScience

Published: May 30, 2024

Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors.

Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors.

Journal: Current oncology (Toronto, Ont.)

Published: February 16, 2024

Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial.

Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 26, 2024

Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Journal: JAMA network open

Published: December 05, 2023

Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials.

Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 26, 2023

Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers.

Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers.

Journal: Nature communications

Published: May 08, 2023

Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study.

Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study.

Journal: International journal of molecular sciences

Published: February 18, 2023

Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers.

Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers.

Journal: NPJ precision oncology

Published: December 26, 2022

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration.

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration.

Journal: NPJ precision oncology

Published: May 08, 2022

Showing 1-12 of 26

Last Updated: 09/26/2026